Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 24, Art. 42 (pp. 560-574)    |    2023       

»

Promising therapies for poisoning with γ- hydroxybutyric acid and its precursors

Yakovlev О.А. 2, Khovpachev A.A.1, Yudin M.A.2,3, Bogacheva A.S.3, Subbotina S.N.2

1 Federal State Budgetary Military Educational Institution of Higher Education «S.M. Kirov Military Medical Academy» of the Ministry of Defense of Russia, 194044, St. Petersburg
2 Federal State Budgetary Institution "State Research Testing Institute of Military Medicine" of the Ministry of Defense of Russia, 195043, St. Petersburg
3 Federal State Budgetary Educational Institution of Higher Education
«I.I. Mechnikov North-Western State Medical University" of the Ministry of Health of Russia 191015, St. Petersburg

Brief summary

The article is devoted to the toxicology and promising means of treating poisoning with γ-hydroxybutyric acid and its precursors - γ-butyrolactone and 1,4- butanediol. The relevance of the study is due to the high frequency of intoxication with these substances, as well as associated withdrawal syndrome and delirium, the lack of effective antidote therapy to date. The epidemiological and toxicological characteristics of poisoning with γ-hydroxybutyric acid and its precursors are described. The literature data on new potentially effective directions and means of correction in the toxicogenic and somatogenic phases of poisoning are summarized. It has been established that reverse agonists of GHB- and GABA-receptors, as well as inhibitors of monocarboxylic acid transport proteins, can be promising directions for further research of acute intoxication therapy. For the treatment of withdrawal delirium, it is advisable to consider atypical antipsychotic drugs, baclofen, acetylcysteine and substitution therapy with γ-hydroxybutyric acid in a smooth dose reduction mode.


Key words

poisoning; γ-hydroxybutyric acid; 1,4-butanediol; γ-butyrolactone; therapy

Reference list

1. Follman K.E., Morris M.E. Treatment of γ-hydroxybutyric acid and γ- butyrolactone overdose with two potent monocarboxylate transporter 1 inhibitors, AZD3965 and AR-C155858. J Pharmacol Exp Ther. 2019; 370 (1): 84-91.


2. Golovko A.I., Golovko S.I., Barinov V.A. i dr. Amneziryushee deistvie «narkotikov iznasilovaniya» kak odna iz prichin ih kriminalnogo ispolzovaniya. Narkologiya. 2013; 12: 74-89.


3. Ostapenko U.N. red. Federalnie klinicheskie rekomendacii. Otravlenie drygimi narkotikami i neytochnennimi psihodisleptikami (gallucinogenami). SPb.: Associaciya klinicheskih toksikologov; 2020. - URL: https://www.toxicology.ru/docs/rek/03_26112020.pdf (Data obrasheniya: 10.03.2020).


4. Golovko A.I., Ivnickii U.U., Reinuk V.L. i dr. Prichini visokoi letalnosti pri peredozirovkah narkoticheskih sredstv iz gryppi sinteticheskih opioidov. Medline.ru. 2020; 21: 141-156. URL: http://www.medline.ru/public/art/ tom21/art13.html (Data obrasheniya 10.01.2023).


5. Sinenchenko A.G., Lodyagin A.N., Batocirenov B.V i dr. Epidemiologiya ostrih otravlenii gamma-gidroksimaslyanoi kislotoi v Sankt-Peterbyrge (po dannim mnogoprofilnogo stacionara). Toksikologicheskii vestnik. 2021; 167 (2): 33-40.


6. Bonitenko E.U., Basharin V.A., Bonitenko U.U. i dr. Deprimiryushie agenti. Novie podhodi k klassifikacii (Diskyssiya). Toksikologicheskii vestnik. 2012; 3(114): 43-46.


7. Maitre M. The γ-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol. 1997; 51 (3): 337-61.


8. Mokhlesi B., Garimella P. S., Joffe A. et al. Street drug abuse leading to critical illness. Intensive Care Med. 2004; 30 (8): 1526-36.


9. Kamal R.M., van Noorden M.S., Wannet W. et al. Pharmacological treatment in γ- hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs. 2017: 31 (1): 51-64.


10. Busardò F.P., Jones A.W. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015; 13 (1): 47-70.


11. Thai D., Dyer J.E., Jacob P. et al. Clinical pharmacology of 1,4-butanediol and γ-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther. 2007; 81 (2): 178-84.


12. Abanades S., Farré M., Barral D. et al. Relative abuse liability of γ- hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol. 2007; 27 (6): 625-38.


13. Snead O.C., Gibson K.M. Gamma-hydroxybutyric acid. N Engl J Med. 2005; 352 (26): 2721-32.


14. Sevak R.J., France C.P., Koek W. Neuroleptic-like effects of γ- hydroxybutyrate: interactions with haloperidol and dizocilpine. Eur J Pharmacol. 2004; 483 (2-3): 289-93.


15. Schep L.J., Knudsen K., Slaughter R.J. et al. The clinical toxicology of γ- hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol. 2012; 50 (6): 458-470.


16. Felmlee M.A., Morse B.L., Morris M.E. Gamma-hydroxybutyric acid: pharmacokinetics, pharmacodynamics, and toxicology. AAPS J. 2021; 23 (1): 22.


17. Carai M. A., Colombo G., Brunetti G. et al. Role of GABA(B) receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid. Eur J Pharmacol. 2001; 428 (3): 315-21.


18. Castelli M. P., Ferraro L., Mocci I. et al. Selective γ-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of γ-hydroxybutyric acid. J Neurochem. 2003; 87 (3): 722-32.


19. Giorgetti A., Busardò F.P., Giorgetti R. Toxicological characterization of GHB as a performance-enhancing drug. Front Psychiatry. 2022; 13. URL: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.846983/full (Data obrasheniya 10.01.2023).


20. Diana M., Mereu G., Mura A. et al. Low doses of γ-hydroxybutyric acid stimulate the firing rate of dopaminergic neurons in unanesthetized rats. Brain Res. 1991; 566 (1-2): 208-11.


21. Brunt T.M., van Amsterdam J.G., van den Brink W. GHB, GBL and 1,4-BD addiction. Curr Pharm Des. 2014; 20 (25): 4076-85.


22. Bonitenko E.U. Toksichnost i osobennosti metabolizma etanola, «syrrogatov» alkogolya i spirtov, sposobnih vizivat massovie otravleniya: obosnovanie napravlenii farmakologicheskoi profilaktiki i terapii intoksikacii. Dis. ? d.m.n. SPb, 2007.


23. Golovko A.I., Barinov V.A., Basharin V.A. i dr. Mehanizmi farmakologicheskoi aktivnosti antideprimiryushih sredstv. Medline.ru. 2012; 13: 157-184. URL: http://www.medline.ru/public/art/tom13/art14.html. (Data obrasheniya 10.01.2023).


24. Schmidt C., Gobaille S., Hechler V. et al. Anti-sedative and anti-cataleptic properties of NCS-382, a γ-hydroxybutyrate receptor antagonist. Eur J Pharmacol. 1991; 203 (3): 393-7.


25. Tang W. The metabolism of diclofenac - enzymology and toxicology per spectives. Curr Drug Metab. 2003; 4 (4): 319-29.


26. Rodriguez-Cruz V., Ren T., Morris M. Drug-drug interaction between diclofenac and γ-hydroxybutyric acid. Biopharm Drug Dispos. 2021; 42 (8): 351-8.


27. Eiden C., Capdevielle D., Deddouche C. et al. Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with γ-butyrolactone withdrawal. J Addict Med. 2011; 5 (4): 302-3.


28. Felmlee M. A., Wang Q., Cui D. et al. Mechanistic toxicokinetic model for γ- hydroxybutyric acid: inhibition of active renal reabsorption as a potential therapeutic strategy. AAPS J. 2010; 12 (3): 407-16.


29. Roiko S.A., Vijay N., Felmlee M.A. et al. Brain extracellular γ- hydroxybutyrate concentrations are decreased by L-lactate in rats: role in the treatment of overdoses. Pharm Res. 2013; 30 (5): 1338-48.


30. Morris M.E., Morse B.L., Baciewicz G.J. et al. Monocarboxylate transporter inhibition with osmotic diuresis increases γ-hydroxybutyrate renal elimination in humans: a proof-of-concept study. J Clin Toxicol. 2011; 1 (2). URL: https://www.longdom.org/open-access/monocarboxylate-transporter-inhibition-with-osmotic-diuresis-increases-gammahydroxybutyrate-renal-elimination-in-humans--47862.html (Data obrasheniya 10.01.2023).


31. Perrault G., Depoortere R., Morel E. et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity // J Pharmacol Exp Ther. 1997. Vol. 280, N 1. R.73-82.


32. Ratomponirina C., Gobaille S., Hodé Y. et al. Sulpiride, but not haloperidol, up-regulates γ- hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998; 346 (2-3): 331-7.


33. Tay E., Lo W.K.W., Murnion B. Current insights on the impact of γ- hydroxybutyrate (GHB) abuse. Subst Abuse Rehabil. 2022; 13: 13-23.


34. Morse B.L., Vijay N., Morris M.E. Gamma-hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol. 2012; 82 (2): 226-35.


35. Lingford-Hughes A., Patel Y., Bowden-Jones O.M. et al. Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. Trials. 2016. 17 (1): 472.


36. Tomko R.L., Jones J.L., Gilmore A.K. et al. N-acetylcysteine: A potential treatment for substance use disorders. Curr Psychiatr. 2018.;17 (6): 30-55.